A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,007actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-18 | actual | When the study began enrolling |
| Primary completion | 2025-12-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-22 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Influenza Immunization
- Health Volunteers
Intervention
- Biological: Trivalent Recombinant Influenza Vaccine
Primary outcomes
what the primary-completion date above is the date OFProportion of Participants Reporting Incidence of Reactions (Local) Using Vaccinees' Perception of Injection (VAPI) Questionnaire (Age Groups [18-49 and 50-64 years])
measured Up to 21 days Post Vaccination
Proportion of Participants Reporting Incidence of reactions (Systemic) Using VAPI Questionnaire (Age Groups [18-49 and 50-64 years])
measured Up to 21 days Post Vaccination
Proportion of Participants Reporting Severity of Reactions (Local and Systemic) Using VAPI Questionnaire (Age groups [18-49 and 50-64 years])
measured Up to 21 days Post Vaccination
Vaccine Acceptability Score Using VAPI Questionnaire (Age groups [18-49 and 50-64 years])
measured Up to 21 days Post Vaccination
Impact on Daily Life Activities Score Using VAPI Questionnaire (Age groups [18-49 and 50-64 years])
measured Up to 21 days Post Vaccination
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed